Olaparib is indicated for the treatment of certain types of ovarian, breast, pancreatic, and prostate cancers in patients who ...

Zydus Lifesciences Ltd announced on Friday (November 7) that it has received tentative approval from the US Food and Drug ...

New hope for advanced prostate cancer patients, with promising new drug combo that targets genes, such as BRCA1, BRCA2, CHEK2 ...

Zydus Lifesciences announced that it has received tentative approval from the United States Food and Drug Administration (USFDA) for its Olaparib Tablets, used in the treatment of certain cancers.

Zydus receives US FDA tentative approval for olaparib tablets, 100 mg and 150 mg: Our Bureau, Mumbai Saturday, November 8, 2025, 10:30 Hrs [IST] Zydus Lifesciences Limited has rec ...

HealthDay News — For patients with metastatic castration-sensitive prostate cancer (mCSPC) with homologous recombination repair (HRR) gene alterations, the addition of niraparib to abiraterone acetate ...

Zydus Lifesciences has received tentative approval from the United States Food and Drug Administration (USFDA) for Olaparib Tablets, 100 mg and 150 mg (USRLD: Lynparza Tablets, 100 mg and 150 mg).

A body that weighs as much as a small airplane should face steep odds against cancer. You may expect that from a creature ...

Ahmedabad: Zydus Lifesciences Limited has received tentative approval from the United States Food and Drug Administration (USFDA) for Olaparib Tablets, 100 mg and 150 mg (USRLD: Lynparza ...

The firm had decreased Q3 sales for precision oncology drugs including Ibrance, Tukysa, and Bosulif, but sales increased for ...